Navigation Links
Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds
Date:7/6/2011

BPH, such as alpha-blockers, have little effect on nocturia and given the significant limitations of other therapies, there are few options available to patients.

VA111913 - Dysmenorrhoea

VA111913 is a small molecule oral drug candidate, discovered by Vantia Therapeutics, and in clinical development for the treatment of dysmenorrhoea, a condition characterised by abnormal contractions of the uterus during menstruation causing severe, and often debilitating pain.

VA111913 acts by blocking vasopressin V1a receptors in the uterus wall to reduce abnormal contraction, thereby offering the potential to be the first drug that directly targets the cause of the pain associated with dysmenorrhoea.

There are currently no targeted therapies for dysmenorrhoea and treatments in common use include over-the-counter painkillers or oral contraceptives used 'off-label'. The market opportunity for a targeted drug for the management of dysmenorrhoea is estimated to be in excess of US$1 billion per year.

Contact details:
Vantia Therapeutics
Andrew Crockett, CEO : +44(0)238-076-3456 /+44(0)787-255-9676
info@vantia.com

Citigate Dewe Rogerson
Chris Gardner / Mark Swallow / Nina Enegren : +44(0)207-638-9571
vantia@citigatedr.co.uk



'/>"/>
SOURCE Vantia Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vantia Therapeutics Pipeline Continues to Mature
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Vantia Therapeutics Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- BioElectronics Corporation (OTC Pink: BIEL), maker of consumer medical ... J. Whelan , President will be interviewed by ... 9am EDT on Wednesday, August 5 th .  To ... http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ Mr. Whelan is ... flagship product, ActiPatch Therapy, is achieving in the UK.  ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, ... of its second clinical development program with a ... CL-H1T.  CL-H1T contains fast-dissolving promethazine ... developed as a treatment for migraine headache pain ... "Many patients with migraine headaches also suffer ...
(Date:8/3/2015)... BOULDER, Colo., Aug. 3, 2015  Encision Inc. (PK:ECIA), ... prevents dangerous stray electrosurgical burns in minimally invasive surgery, ... quarter that ended June 30, 2015. The ... a quarterly net loss of $213 thousand, or $(0.02) ... $2.476 million for a net loss of $202 thousand, ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... Association for the Study of the ... Liver Annual Meeting -, SAN ... its Phase 2 study of its lead,compound, MitoQ(R) (mitoquinone) in liver disease. ... the Study of the Liver,(EASL) Annual Meeting, being held April 23 - ...
... VALENCIA, Calif., April 10 MannKind,Corporation (Nasdaq: ... to,the announcement by Pfizer Inc. that over the ... 4,740 patients treated with Exubera developed lung,cancer, although ... to,determine whether this observation was related to Exubera. ...
Cached Medicine Technology:Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R) 2MannKind Addresses Pfizer's Announcement Regarding Exubera 2MannKind Addresses Pfizer's Announcement Regarding Exubera 3
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director of ... The new facility is licensed under Dignity Health Arizona General Hospital , ... an excellent leader and will ensure our new freestanding emergency room delivers the highest ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Foot ... of a new associate podiatrist, creating the largest medical practice in the Mid-Atlantic region ... ankle medicine. FASMA operates 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is ...
(Date:8/3/2015)... Louisville, KY (PRWEB) , ... August 03, 2015 , ... ... suffer from lower back pain at least once in their lives. Often time, low ... bulges. Until recently, disc herniations could only be managed clinically with powerful pain medication ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... and connective tissues of a woman’s pelvic organs (uterus, bladder, and bowel) ... heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, and the aging ...
Breaking Medicine News(10 mins):Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2
... a statement released by Ranbaxy Pharmaceuticals Inc (RPI), they ... Award // from Wal-Mart, the largest chain store in ... of 2005. Wal-Mart Stores is a global company with ... stores and wholesale clubs across 10 countries. , ...
... cells that are responsible for causing epileptic seizures // ... of Medicine have identified glutamate receptor cells in the ... of glutamate when there is brain action that’s associated ... that will affect the protective glutamate receptors in increasing ...
... University of Michigan, who had long earlier published their findings ... ADHD, have come up with the results from the next ... the two. ,The follow up data of the ... who had snored regularly through their childhood are four times ...
... Cancer Institute and collaborating institutions have found sections of ... genes may lurk. , ,In a study ... Research, the researchers used single nucleotide polymorphism (SNP) array ... genes, to identify regions of chromosomes where genes were ...
... Vaccines for prophylaxis are well known. Famous vaccines include ... etc.; Therapeutic vaccines to cure a condition are more ... include the ones against HIV and hepatitis. The therapeutic ... combat an infectious agent, such as a virus. Now ...
... Statins are known to successfully treat atherosclerosis, the narrowing ... whether the drugs could also treat a similar condition ... valve in the heart. , ,According to a ... high doses of cholesterol-lowering drugs actually fail to treat ...
Cached Medicine News:Health News:Possible location of lung cancer genes found 2Health News:Understanding Chronic Infections May Help in Developing Therapeutic Vaccines 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: